LLY vs PEPG

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Score Change Explanation: The previous score of 80/100 (8/10) on 2026-02-13 was based on PepGen's robust EDO platform and lead candidate PGN-EDO51 for DMD, anticipating future market leadership. However, since the last analysis, material adverse events have significantly altered the investment thesis and risk profile. On March 4, 2026, the FDA placed a partial clinical hold on the FREEDOM2-DM1 Pha...